Biotech Values

[Mufaso]

Including Ocliva, I suspect billions have been spent in failed NASH trials with nothing to show for it. One would think the market is very attractive given that so many keep trying.

Below is a partial list of notable drugs (I'm sure there are more) that have failed in Nash, along with MOA and trial phase completed:

 Selonsertib (Gilead)		ASK1 inhibitor		Multiple Ph 3  
 Simtuzumab  (Gilead)		Anti-Loxl2 MAb		Ph 2  
 Px-102 (Gilead)		FXR agonist		Ph 2  
 Elafibranor (Genfit)		PPARa/d agonist		Ph 3  
 Emricasan (Conatus)		FXR agonist		Ph 2b  
 Ocaliva (Intercept ) 		CETP inhibitor		Mult Ph 3  
 Seladelpar (Cymabay ) 		PPAR-delta agonist	Ph 2b  
 Semaglutide (NOVO) 		GLP-1 ag		Ph 2  
 PF-06882961 (Pfizer)		GLP-1 ag		Ph 1 
 PF 06835919 (Pfizer)		Ketohexokinase inh	Ph 2 
 NGM-219 (NGM     )		UPR inducer		Ph 2b 
 BI 1467335(Boehringer)		Pan-caspase inh		ph 2